CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
High ImpactOriginal article

Lilly bets $2.8B upfront on psychedelics in deal to buy AtaiBeckley

Positive
AI Analysis

Summary

Eli Lilly announced the acquisition of psychedelic drug developer AtaiBeckley for $2.8 billion upfront, reflecting major pharmaceutical companies' growing interest in the psychedelics sector.

Importance:8/10
Sentiment:
0.60
acquisitionpsychedelicsbig pharmaM&A
Related Companies

Read the original article

Published by Endpoints News on July 16, 2026 11:09 AM

Read Original